

**State of Oklahoma
Oklahoma Health Care Authority
Botulinum Toxins Prior Authorization Form**

BILLING INFORMATION

Member Name: _____ **Date of Birth:** _____ **Weight:** _____
Member ID#: _____ **HCP/CS Code:** _____ **CPT Code:** _____
Dose: _____ **Frequency:** _____ **Start Date:** _____
Provider Name: _____ **Medical Specialty:** _____
OHCA Provider #: _____ **Phone:** _____ **Fax:** _____

TO BE COMPLETED BY PRESCRIBER

Page 1 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.

Diagnosis: _____ (Diagnosis is required for all Botulinum Toxins)

Chronic Migraine Diagnosis: please complete the following section. (Only Botox® will be approved.)

1. Number of headache days per month? _____
2. Number of migraine days per month? _____
 - a. How long has the member had chronic migraines at the frequency listed above? _____ months
3. What is the average duration of migraines? _____ hours
4. Have the following medical conditions known to cause or exacerbate migraines been ruled out/treated?
 - a. Increased intracranial pressure (e.g., tumor, pseudotumor cerebri, central venous thrombosis)?
Yes ___ No ___
 - b. Decreased intracranial pressure (e.g., post-lumbar puncture headache, dural tear after trauma)?
Yes ___ No ___
5. Has migraine headache exacerbation secondary to the following medication therapies or conditions been ruled out and/or treated?
 - a. Hormone replacement therapy or hormone-based contraceptives? Yes ___ No ___
 - b. Chronic insomnia? Yes ___ No ___
 - c. Obstructive sleep apnea? Yes ___ No ___
6. Is the member taking any of the following medications known to cause medication overuse or rebound headaches in the absence of intractable conditions known to cause chronic pain?
 - a. Butalbital-containing medications? Yes ___ No ___
 - b. Opioid-containing medications? Yes ___ No ___
 - c. Analgesic medications including acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs)? Yes ___ No ___
 - d. Ergotamine-containing medications? Yes ___ No ___
 - e. Triptans? Yes ___ No ___

If yes, to any of medications above, please list the medication(s) and the number of days per month taken: _____

7. Has the member failed at least 2 medications with different mechanisms of action typically used for migraine prevention (antihypertensives, anticonvulsants, antidepressants, etc)? Yes ___ No ___ If yes, please list:
 Medication _____ Date Span _____ Dosing _____
 Medication _____ Date Span _____ Dosing _____
 Medication _____ Date Span _____ Dosing _____
8. Has the member been evaluated by a neurologist for chronic migraine headaches within the past 6 months?
 Yes ___ No ___ If yes, please include name of neurologist recommending Botox® treatment: _____
9. Does the member currently use tobacco? Yes ___ No ___

Please complete and return all pages. Failure to complete all pages will result in processing delays.

<p><u>PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:</u></p> <p align="center">University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit</p> <p align="center">Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4</p>	<p align="center"><u>CONFIDENTIALITY NOTICE</u></p> <p><i>This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.</i></p>
---	---

**State of Oklahoma
Oklahoma Health Care Authority
Botulinum Toxins Prior Authorization Form**

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____

TO BE COMPLETED BY PRESCRIBER

Page 2 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.

Overactive Bladder Diagnosis: please complete the following section. (Only Botox® will be approved.)

1. Number of urinary incontinence episode(s) per day while on medication? _____
2. Have urodynamic studies been performed? Yes ___ No ___ If yes, include date _____
3. Has member participated in behavioral therapy? Yes ___ No ___
If yes, please give length of therapy and reason for therapy failure: _____
4. Has member used at least 3 anti-muscarinic medications for the treatment of overactive bladder? Yes ___ No ___
If yes, please list:
Medication _____ Date Span _____ Dosing _____
Medication _____ Date Span _____ Dosing _____
Medication _____ Date Span _____ Dosing _____
5. Does the member or caregiver have the ability to catheterize? Yes ___ No ___

Neurogenic Bladder Diagnosis: please complete the following section. (Only Botox® will be approved.)

1. Have urodynamic studies been performed? Yes ___ No ___ If yes, include date _____
2. What is the specific underlying pathological urologic dysfunction (such as small bladder capacity <400 cc, high detrusor pressure, etc)? _____
3. Does member keep diary of fluid intake, voiding/catheterization times and amounts or number of diapers/pads used daily? Yes ___ No ___
4. Clinical reason for failure of anticholinergic medication therapy? _____
5. Does the member have physical and cognitive ability to self-catheterize or access to caregiver? Yes ___ No ___

Please complete and return all pages. Failure to complete all pages will result in processing delays.

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

<p><u>PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:</u></p> <p align="center">University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit</p> <p align="center">Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4</p>	<p align="center"><u>CONFIDENTIALITY NOTICE</u></p> <p><i>This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.</i></p>
--	---